Zibotentan for the treatment of castrate-resistant prostate cancer

By Shepard Dale R   Dreicer Robert  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 899-908

Informa Healthcare

Access to resources Recommend Favorite

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α_v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

By Chu Franklin   Picus Joel   Fracasso Paula   Dreicer Robert   Lang Zhihui   Foster Brenda  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 674-679

Springer Publishing Company

Access to resources Recommend Favorite

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D   van Diest Paul J   van der Wall Elsken   Gelderblom Hans  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

By Warren Ruth   Liu Glenn  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 8, 2008-08 ,pp. : 1237-1245

Informa Healthcare

Access to resources Recommend Favorite

New therapies for castrate-resistant prostate cancer

By Williams Stephen B   Lay Aaron H   Lau Clayton S   Josephson David Y   Wilson Timothy G   Choueiri Toni K   Pal Sumanta K  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2069-2074

Informa Healthcare

Access to resources Recommend Favorite